Amphastar P (AMPH)vsZoetis Inc (ZTS)
AMPH
Amphastar P
$26.68
-2.59%
HEALTHCARE · Cap: $1.03B
ZTS
Zoetis Inc
$70.30
-1.58%
HEALTHCARE · Cap: $29.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1205% more annual revenue ($9.53B vs $730.02M). ZTS leads profitability with a 27.7% profit margin vs 10.8%. AMPH appears more attractively valued with a PEG of 2.77. AMPH earns a higher WallStSmart Score of 59/100 (C).
AMPH
Buy59
out of 100
Grade: C
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.6%
Fair Value
$39.51
Current Price
$26.68
$12.83 discount
Margin of Safety
+10.8%
Fair Value
$144.17
Current Price
$70.30
$73.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 21.6%
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
4.7% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Trading at 9.0x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMPH
The strongest argument for AMPH centers on Price/Book, P/E Ratio, Operating Margin.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : AMPH
The primary concerns for AMPH are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMPH profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
AMPH carries more volatility with a beta of 0.92 — expect wider price swings.
AMPH is growing revenue faster at 5.4% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
AMPH scores higher overall (59/100 vs 58/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amphastar P
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?